Bedaquiline Correlation to QT Interval Prolongation in DR-TB Patients
Introduction: The regimen of drug-resistant tuberculosis (DR-TB) is Bedaquiline. One of the adverse events is QT interval prolongation, which can increase the risk of Torsade de Pointes (TdP) and lead to death. DR-TB patient screening before starting the treatment and monitoring QT interval during t...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Universitas Airlangga
2022-09-01
|
| Series: | Jurnal Respirasi |
| Subjects: | |
| Online Access: | https://e-journal.unair.ac.id/JR/article/view/35247 |
| _version_ | 1828172204851855360 |
|---|---|
| author | Vandu Primadana Indra Yovi Dyah Siswanti Estiningsih |
| author_facet | Vandu Primadana Indra Yovi Dyah Siswanti Estiningsih |
| author_sort | Vandu Primadana |
| collection | DOAJ |
| description | Introduction: The regimen of drug-resistant tuberculosis (DR-TB) is Bedaquiline. One of the adverse events is QT interval prolongation, which can increase the risk of Torsade de Pointes (TdP) and lead to death. DR-TB patient screening before starting the treatment and monitoring QT interval during the treatment should be performed. This study aimed to determine Bedaquiline correlation to QT interval prolongation in DR-TB patients.
Methods: This was a retrospective study using an observational design by viewing medical records of DR-TB patients who underwent treatment from January 2019 to March 2022.
Results: This study involved 46 DR-TB patients with an average age of 41.4 years old, and 58.7% were males with a regimen of Bedaquiline. The comparison of Baseline QT intervals before and after one month of therapy showed QT interval prolongation (457.1 ± 18.2 ms and 443.8 ± 10.2 ms; p < 0.001). The comparison of QT intervals before the therapy and six months after the therapy showed prolongation QT intervals (443.8 ± 10.2 ms and 458.4 ± 23.7 ms; p < 0.001). QT intervals after one month of therapy compared to six months after the therapy showed insignificant slight prolongation (457.1 ± 18.2 ms and 458.4 ± 23.7 ms; p = 0.587).
Conclusion: QT interval prolongation occurred in DR-TB patients who received treatment using Bedaquiline regimen. It was seen significantly between baseline QT interval and after receiving the therapy for one month and six months. |
| first_indexed | 2024-04-12T03:37:25Z |
| format | Article |
| id | doaj.art-1bb1e2b26fc74a968a381d40fc4f30d7 |
| institution | Directory Open Access Journal |
| issn | 2407-0831 2621-8372 |
| language | English |
| last_indexed | 2024-04-12T03:37:25Z |
| publishDate | 2022-09-01 |
| publisher | Universitas Airlangga |
| record_format | Article |
| series | Jurnal Respirasi |
| spelling | doaj.art-1bb1e2b26fc74a968a381d40fc4f30d72022-12-22T03:49:22ZengUniversitas AirlanggaJurnal Respirasi2407-08312621-83722022-09-0183140146https://doi.org/10.20473/jr.v8-I.3.2022.140-146Bedaquiline Correlation to QT Interval Prolongation in DR-TB PatientsVandu Primadana0https://orcid.org/0000-0001-8169-7660Indra Yovi1https://orcid.org/0000-0001-8749-8101Dyah Siswanti Estiningsih2Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Riau/Arifin Achmad General Hospital, Pekanbaru, Indonesia.Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Riau/Arifin Achmad General Hospital, Pekanbaru, Indonesia.Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Riau/Arifin Achmad General Hospital, Pekanbaru, Indonesia.Introduction: The regimen of drug-resistant tuberculosis (DR-TB) is Bedaquiline. One of the adverse events is QT interval prolongation, which can increase the risk of Torsade de Pointes (TdP) and lead to death. DR-TB patient screening before starting the treatment and monitoring QT interval during the treatment should be performed. This study aimed to determine Bedaquiline correlation to QT interval prolongation in DR-TB patients. Methods: This was a retrospective study using an observational design by viewing medical records of DR-TB patients who underwent treatment from January 2019 to March 2022. Results: This study involved 46 DR-TB patients with an average age of 41.4 years old, and 58.7% were males with a regimen of Bedaquiline. The comparison of Baseline QT intervals before and after one month of therapy showed QT interval prolongation (457.1 ± 18.2 ms and 443.8 ± 10.2 ms; p < 0.001). The comparison of QT intervals before the therapy and six months after the therapy showed prolongation QT intervals (443.8 ± 10.2 ms and 458.4 ± 23.7 ms; p < 0.001). QT intervals after one month of therapy compared to six months after the therapy showed insignificant slight prolongation (457.1 ± 18.2 ms and 458.4 ± 23.7 ms; p = 0.587). Conclusion: QT interval prolongation occurred in DR-TB patients who received treatment using Bedaquiline regimen. It was seen significantly between baseline QT interval and after receiving the therapy for one month and six months.https://e-journal.unair.ac.id/JR/article/view/35247bedaquilinedrug-resistant tuberculosistorsade de pointestuberculosisqt interval |
| spellingShingle | Vandu Primadana Indra Yovi Dyah Siswanti Estiningsih Bedaquiline Correlation to QT Interval Prolongation in DR-TB Patients Jurnal Respirasi bedaquiline drug-resistant tuberculosis torsade de pointes tuberculosis qt interval |
| title | Bedaquiline Correlation to QT Interval Prolongation in DR-TB Patients |
| title_full | Bedaquiline Correlation to QT Interval Prolongation in DR-TB Patients |
| title_fullStr | Bedaquiline Correlation to QT Interval Prolongation in DR-TB Patients |
| title_full_unstemmed | Bedaquiline Correlation to QT Interval Prolongation in DR-TB Patients |
| title_short | Bedaquiline Correlation to QT Interval Prolongation in DR-TB Patients |
| title_sort | bedaquiline correlation to qt interval prolongation in dr tb patients |
| topic | bedaquiline drug-resistant tuberculosis torsade de pointes tuberculosis qt interval |
| url | https://e-journal.unair.ac.id/JR/article/view/35247 |
| work_keys_str_mv | AT vanduprimadana bedaquilinecorrelationtoqtintervalprolongationindrtbpatients AT indrayovi bedaquilinecorrelationtoqtintervalprolongationindrtbpatients AT dyahsiswantiestiningsih bedaquilinecorrelationtoqtintervalprolongationindrtbpatients |